The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments
Open accessAbstract
Objective: To perform a meta-analysis of randomized, blinded, multiple sclerosis (MS) clinical trials to test the hypothesis that efficacy of immunomodulatory disease-modifying therapies (DMTs) on MS disability progression is strongly dependent on age. Methods: We performed a literature search with pre-defined criteria and extracted relevant features from 38 clinical trials that assessed efficacy of DMTs on disability progression. We fit a linear regression, weighted for trial sample size and duration, to examine the hypothesis that age has a defining effect on the therapeutic efficacy of immunomodulatory DMTs. Results: More than 28,000 MS subjects participating in trials of 13 categories of immunomodulatory drugs are included in the meta-analysis. The efficacy of immunomodulatory DMTs on MS disability strongly decreased with advancing age (R2 = 0.6757, p = 6.39e-09). Inclusion of baseline EDSS did not significantly improve the model. The regression predicts zero efficacy beyond approximately age 53 years. The comparative efficacy rank derived from the regression residuals differentiates high and low efficacy drugs. High efficacy drugs outperform low efficacy drugs in inhibiting MS disability only for patients younger than 40.5 years. Conclusions: The meta-analysis supports the notion that progressive MS is simply a later stage of the MS disease process and that age is an essential modifier of a drug efficacy. Higher efficacy treatments exert their benefit over lower efficacy treatments only during early stages of MS, and, after age 53, the model suggests that there is no predicted benefit to receiving immunomodulatory DMTs for the average MS patient.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
Neurotoxic reactive astrocytes are induced by activated microglia
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971
New Multiple Sclerosis Phenotypic Classification
Lublin, F. D. (2014) · European Neurology · doi:10.1159/000367614 · Cited by 4,259
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
The International Multiple Sclerosis Genetics Consortium & The Wellcome Trust Case Control Consortium 2 (2011) · Nature · doi:10.1038/nature10251 · Cited by 2,697
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H.-P., Hemmer, B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606468 · Cited by 1,905
Magliozzi, R., Howell, O., Vora, A., Serafini, B., Nicholas, R., Puopolo, M., Reynolds, R., & Aloisi, F. (2006) · Brain · doi:10.1093/brain/awm038 · Cited by 1,443
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Fox, R. J., Miller, D. H., Phillips, J. T., Hutchinson, M., Havrdova, E., Kita, M., Yang, M., Raghupathi, K., Novas, M., Sweetser, M. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206328 · Cited by 1,355
Progressive multiple sclerosis: pathology and pathogenesis
Lassmann, H., van Horssen, J., & Mahad, D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.168 · Cited by 1,033
Multiple Sclerosis Severity Score: Using disability and disease duration to rate disease severity
Roxburgh, R. H. S. R., Seaman, S. R., Masterman, T., Hensiek, A. E., Sawcer, S. J., Vukusic, S., Achiti, I., Confavreux, C., Coustans, M., le Page, E., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000156155.19270.f8 · Cited by 963
Hawker, K., O'Connor, P., Freedman, M. S., Calabresi, P. A., Antel, J., Simon, J., Hauser, S., Waubant, E., Vollmer, T., Panitch, H., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21867 · Cited by 934
Natural history of multiple sclerosis: a unifying concept
Confavreux, C., & Vukusic, S. (2006) · Brain · doi:10.1093/brain/awl007 · Cited by 905
A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis
Magliozzi, R., Howell, O. W., Reeves, C., Roncaroli, F., Nicholas, R., Serafini, B., Aloisi, F., & Reynolds, R. (2010) · Annals of Neurology · doi:10.1002/ana.22230 · Cited by 747
A Modern Approach to Regression with R
Sheather, S. (2009) · Springer Texts in Statistics · doi:10.1007/978-0-387-09608-7 · Cited by 692
Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis
Trapp, B. D., & Stys, P. K. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70043-2 · Cited by 621
Age at disability milestones in multiple sclerosis
Confavreux, C., & Vukusic, S. (2006) · Brain · doi:10.1093/brain/awh714 · Cited by 525
Kipnis, J., Cohen, H., Cardon, M., Ziv, Y., & Schwartz, M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402268101 · Cited by 510
Fischer, M. T., Sharma, R., Lim, J. L., Haider, L., Frischer, J. M., Drexhage, J., Mahad, D., Bradl, M., van Horssen, J., & Lassmann, H. (2012) · Brain · doi:10.1093/brain/aws012 · Cited by 507
Will the real multiple sclerosis please stand up?
Stys, P. K., Zamponi, G. W., van Minnen, J., & Geurts, J. J. G. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3275 · Cited by 475
Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis.
Choi, S. R., Howell, O. W., Carassiti, D., Magliozzi, R., Gveric, D., Muraro, P. A., Nicholas, R., Roncaroli, F., & Reynolds, R. (2012) · Brain · doi:10.1093/brain/aws189 · Cited by 386
Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis
Campbell, G. R., Ziabreva, I., Reeve, A. K., Krishnan, K. J., Reynolds, R., Howell, O., Lassmann, H., Turnbull, D. M., & Mahad, D. J. (2011) · Annals of Neurology · doi:10.1002/ana.22109 · Cited by 386
Sormani, M. P., Arnold, D. L., & De Stefano, N. (2014) · Annals of Neurology · doi:10.1002/ana.24018 · Cited by 297
The (mis)use of overlap of confidence intervals to assess effect modification
Knol, M. J., Pestman, W. R., & Grobbee, D. E. (2011) · European Journal of Epidemiology · doi:10.1007/s10654-011-9563-8 · Cited by 249
for the AFFIRM and SENTINEL Investigators, Hutchinson, M., Kappos, L., Calabresi, P. A., Confavreux, C., Giovannoni, G., Galetta, S. L., Havrdova, E., Lublin, F. D., Miller, D. H., et al. (2009) · Journal of Neurology · doi:10.1007/s00415-009-0093-1 · Cited by 234
Sormani, M. P., Bonzano, L., Roccatagliata, L., Cutter, G. R., Mancardi, G. L., & Bruzzi, P. (2009) · Annals of Neurology · doi:10.1002/ana.21606 · Cited by 223
Efficient central nervous system remyelination requires T cells
Bieber, A. J., Kerr, S., & Rodriguez, M. (2003) · Annals of Neurology · doi:10.1002/ana.10578 · Cited by 196
Devonshire, V., Havrdova, E., Radue, E. W., O'Connor, P., Zhang-Auberson, L., Agoropoulou, C., Häring, D. A., Francis, G., & Kappos, L. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70056-x · Cited by 184
Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis
Komori, M., Blake, A., Greenwood, M., Lin, Y. C., Kosa, P. F., Ghazali, D., Winokur, P. N., Natrajan, M. S., Wuest, S. C., Romm, E., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24408 · Cited by 158
Self-citationInsufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis
Komori, M., Lin, Y. C., Cortese, I. C. M., Blake, A., Ohayon, J. M., Cherup, J., Marić, D., Kosa, P. F., Wu, T., & Bielekova, B. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.293 · Cited by 153
Self-citationMiller, A., O'Connor, P. W., Wolinsky, J. S., Confavreux, C., Kappos, L., Olsson, T. P., Truffinet, P., Wang, L., D’Castro, L., Comı, G., et al. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458512450354 · Cited by 97
Schwartz, M. (2010) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2010.01.010 · Cited by 96
McMahon, J. M., McQuaid, S., Reynolds, R., & FitzGerald, U. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458512438455 · Cited by 65
Yang, R., & Dunn, J. F. (2015) · Scientific Reports · doi:10.1038/srep16477 · Cited by 61
A new paraclinical CSF marker for hypoxia‐like tissue damage in multiple sclerosis lesions
Lassmann, H., Reindl, M., Rauschka, H., Berger, J., Aboul‐Enein, F., Berger, T., Zurbriggen, A., Lutterotti, A., Brück, W., Weber, J. R., et al. (2003) · Brain · doi:10.1093/brain/awg127 · Cited by 53
A Complex Role of Herpes Viruses in the Disease Process of Multiple Sclerosis
Wuest, S. C., Mexhitaj, I., Chai, N. R., Romm, E., Scheffel, J., Xu, B., Lane, K. C., Wu, T., & Bielekova, B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105434 · Cited by 37
Self-citationPharmacodynamic effects of daclizumab in the intrathecal compartment
Komori, M., Kosa, P. F., Stein, J., Zhao, V., Blake, A., Cherup, J., Sheridan, J. P., Wu, T., & Bielekova, B. (2017) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.427 · Cited by 16
Self-citationSustained reduction of MS disability: New player in comparing disease-modifying treatments
Bielekova, B., & Tintoré, M. (2016) · Neurology · doi:10.1212/wnl.0000000000003314 · Cited by 3
Self-citation
Cited by
Jakimovski, D., Bittner, S., Zivadinov, R., Morrow, S. A., Benedict, R. H., Zipp, F., & Weinstock-Guttman, B. (2024) · The Lancet · doi:10.1016/s0140-6736(23)01473-3 · Cited by 597
Ardern, C. L., Büttner, F., Andrade, R., Weir, A., Ashe, M. C., Holden, S., Impellizzeri, F. M., Delahunt, E., Dijkstra, H. P., Mathieson, S., et al. (2022) · British Journal of Sports Medicine · doi:10.1136/bjsports-2021-103987 · Cited by 458
Werneburg, S., Jung, J., Kunjamma, R. B., Ha, S.-K., Luciano, N. J., Willis, C. M., Gao, G., Biscola, N. P., Havton, L. A., Crocker, S. J., et al. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.004 · Cited by 440
Harding, K., Williams, O., Willis, M., Hrastelj, J., Rimmer, A., Joseph, F., Tomassini, V., Wardle, M., Pickersgill, T., Robertson, N., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.4905 · Cited by 366
Epidemiology and treatment of multiple sclerosis in elderly populations
Vaughn, C. B., Jakimovski, D., Kavak, K. S., Ramanathan, M., Benedict, R. H. B., Zivadinov, R., & Weinstock-Guttman, B. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0183-3 · Cited by 306
Metadata
- Authors
- Weideman, A. M., Tapia-Maltos, M. A., Johnson, K., Greenwood, M., & Bielekova, B.
- Venue
- Frontiers in Neurology
- Publisher
- Frontiers Media SA
- Published
- 2017-11-10
- Volume
- 8
- Pages
- 577-577
- ISSN
- 1664-2295 (ISSN-L)
- OpenAlex
- W2767362256
- Cited by
- 310
- References
- 39
- FWCI
- 3.52
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.